Hereditary prostate cancer

2008-06-01   Johanna Schleutker 

Institute of Medical Technology, University of Tampere, Tampere University Hospital, Tampere, Finland

Identity

Name

Hereditary prostate cancer

Alias

Familial prostate cancer

Inheritance

The inherited form is predicted to account for 5-9% of prostate cancers. Multiple forms of inheritance have been suggested based on segregation analyses: autosomal dominant (rare, high-penetrant gene, mostly linked to disease onset at a younger age), autosomal recessive, X-linked (mostly linked to late-onset cases), multi-factorial and co-dominant.

Omim

300147 , 601518 , 602759 , 608658 , 609558 , 610321 , 610997 , 614731

Mesh

C537243

Orphanet

1331 Familial prostate cancer

Umls

C2931456

Clinics

Note

Hereditary\/familial prostate cancer is a heterogeneous disease entity with complex genetics.

Phenotype and clinics

The definition of hereditary prostate cancer (HPC) is based on the family history (pedigree). The suggested criteria include 1) nuclear family with three (or more) cases of prostate cancer, 2) prostate cancer in three successive generations, or 3) at least two men diagnosed with the disease before the age of 55 years. Familial aggregation of cases that dont fulfill the HPC criteria are defined as familial prostate cancer. The onset of HPC is on average 6 years earlier than of sporadic prostate cancer but the clinical course is otherwise no different.

Neoplastic risk

There is a greater risk of prostate cancer for brothers and sons of men with the disease. The relative risk of prostate cancer is about two-fold in first-degree relatives of affected men and the risk increases with increasing number of affected relatives and their decreasing age at diagnosis. The incidence and absolute risk of prostate cancer varies among different ethnic backgrounds. However, increase in relative risk for males with a positive family history of the disease is essentially the same in all studied populations.
In epidemiological studies increased risk of breast cancer, ovarian cancer, gastric cancer and liver cancer, Hodgkins disease, leukaemia and melanoma have been detected in relatives of prostate cancer patients.

Treatment

Curative treatment is possible for localized prostate cancer.
Men with strong positive family history should be offered risk assessment and regular follow-ups. Early detection is possible through PSA (prostate specific antigen) testing and DRE (digital rectal examination). In rare families where known mutations are segregating, genetic testing may be possible.

Prognosis

Prognosis is more dependent on extent of the disease at diagnosis than on the genetic susceptibility. PSA testing is as efficient in HPC families as in the general population.

Genes involved and Proteins

Note

There is strong evidence from epidemiological and family studies in support of genetic predisposition to prostate cancer. Despite this, no major susceptibility gene has been identified. It is commonly accepted that predisposition may be mediated through multiple common low-to-moderate-penetrance risk alleles. Only few rare (high-risk) mutations in candidate genes have been found in families fulfilling the HPC definition. Familial prostate cancer is likely a mixture of cases caused by dominant high-risk genes, risk-modulating genes, environmental risk factors and ageing.

Alias

HPC1RNS4PRCA1MGC104972MGC133329DKFZp781D08126

Note

Ribonuclease L (2,5-oligoisoadenylate synthetase-dependent), encodes an antiviral, proapoptotic and interferon-activated RNase.

Description

6 coding exons spanning 13,337 bases of genomic DNA, mRNA has a size of 4,166 kb.

Expression

Highly expressed in spleen and thymus followed by prostate, testis, uterus, small intestine, colon and peripheral blood leukocytes.

Localisation

Cytoplasm and mitochondrion.

Function

Endoribonuclease, mediator of interferon action, which play a role in mediating resistance to virus infection and apoptosis. Possibly play a central role in the regulation of mRNA turnover.

Homology

mouse, rat

Germinal

About 20 mutations\/variants described. Met1Ile, Glu265>Stop and Arg462Gln were the first identified risk alleles for HPC. Arg462Gln has three times reduced enzymatic activity. A founder 471delAAAG has been found in Ashkenazi Jews. Glu265>Stop and Asp\/Asp genotype of codon 541 have been associated with familial prostate cancer risk in Finnish and Japanese populations, respectively. These mutations are often associated with early age of onset.

Alias

HPC2ELC2FLJ10530FLJ36693FLJ42848

Description

24 coding exons spanning 25,658 bases of genomic DNA, mRNA has a size of 3,026.

Note

Zinc phosphodiesterase ELAC protein 2.

Description

Protein product of 826 amino acids; 92,219 Da.

Expression

Highly expressed in heart, placenta, liver, skeletal muscle, kidney, pancreas, testis and ovary. Weakly expressed in brain, lung, spleen, thymus, prostate, small intestine, colon and leukocytes.

Localisation

Nucleus

Function

Zinc phosphodiesterase, which displays some tRNA 3-processing endonuclease activity. Probably involved in tRNA maturation, by removing a 3-trailer from precursor tRNA.

Homology

mouse, rat

Germinal

4 mutations associated with prostate cancer susceptibility, altogether about 20 variants described. Two truncating nonsense mutations mutations have been found in HPC families. In addition, two common missense variants, Ser217Leu and Ala541Thr, have also been associated with familial prostate cancer susceptibility.

Alias

CD204SCARA1SR-AphSR1phSR2

Note

Three isoforms. Isoform type 1 has a total length of 67,904; processed length of 1,356 and protein product length of 451. Isoform 2 has a total length of 53,475; processed length of 2,960 and mRNA product length of 2,960. Isoform 3 has a total length of 67,904; processed length of 1,167 and protein product length of 388. The isoforms type 1 and type 2 are functional receptors and are able to mediate the endocytosis of modified low density lipoproteins (LDLs). The isoform type 3 does not internalize modified LDL (acetyl-LDL) despite having the domain shown to mediate this function in the types 1 and 2 isoforms. It has an altered intracellular processing and is trapped within the endoplasmic reticulum, making it unable to perform endocytosis.

Description

9 (8) coding exons spanning 84.914 bases of genomic DNA, mRNA has a size of 1,167-3,761.

Note

Macrophage scavenger receptor types I and II

Description

  • I 451 amino acids, 49,762 Da;
  • II 358 amino acids, 39,584 Da
  • Expression

    Widely expressed. Highly expressed in heart, placenta, liver, skeletal muscle, kidney, pancreas, testis and ovary. Weakly expressed in brain, lung, spleen, thymus, prostate, small intestine, colon and leukocytes.

    Localisation

    Membrane; Single-pass type II membrane protein.

    Function

    Membrane glycoproteins implicated in the pathologic deposition of cholesterol in arterial walls during atherogenesis. Two types of receptor subunits exist. These receptors mediate the endocytosis of a diverse group of macromolecules, including modified low density lipoproteins (LDL).

    Homology

    mouse, rat

    Germinal

    Truncating mutations originally found in African-American and European-American men. Arg293X truncating mutation results in a dominant negative mutant of the gene.

    To be noted

    Note

    In addition to the three strong candidate susceptibility genes (RNASEL, ELAC2 and MSR1), a number of other loci have been identified in genome-wide genetic linkage studies using HPC families. These include for example 1p35-36 (CAPB), 1q42-43 ( PCAP ), 16q23, 17q22, 20q13 ( HPC20 ) and Xq27-28 ( HPCX ). However, many of the reported loci have been hard to validate in other populations and therefore the results of the linkage analyses have remained disparate. More recently, using genome-wide SNP analyses, even more susceptibility loci have been localized, including repeatedly detected 3p, 8q24, 10q11, 11q13, 17q and Xp11. In addition, association with familial prostate cancer has been detected with mutations of CHEK2 (22q12.1), BRCA2 (13q12), CDKN1B (12p13.1-p12), PON1 (7q21.3), SRD5A2 (2p23) and PALB2 (16p12.1) although the results are not fully consistent in all populations and ethnic groups studied.

    Bibliography

    Pubmed IDLast YearTitleAuthors
    159060962005A major locus for hereditary prostate cancer in Finland: localization by linkage disequilibrium of a haplotype in the HPCX region.Baffoe-Bonnie AB et al
    108201302000Evidence for a prostate cancer-susceptibility locus on chromosome 20.Berry R et al
    95856071998Predisposing gene for early-onset prostate cancer, localized on chromosome 1q42.2-43.Berthon P et al
    171662382007What should a urologist know about hereditary predisposition to prostate cancer?Bratt O et al
    174784742007Compelling evidence for a prostate cancer gene at 22q12.3 by the International Consortium for Prostate Cancer Genetics.Camp NJ et al
    117993942002Germline mutations in the ribonuclease L gene in families showing linkage with HPC1.Carpten J et al
    15656271992Mendelian inheritance of familial prostate cancer.Carter BS et al
    99502401999Family history and prostate cancer risk in a population-based cohort of Iowa men.Cerhan JR et al
    150263352004A polymorphism in the CDKN1B gene is associated with increased risk of hereditary prostate cancer.Chang BL et al
    127409112003Oligogenic segregation analysis of hereditary prostate cancer pedigrees: evidence for multiple loci affecting age at onset.Conlon EM et al
    113096862001Segregation analyses of 1,476 population-based Australian families affected by prostate cancer.Cui J et al
    125337882003Mutations in CHEK2 associated with prostate cancer risk.Dong X et al
    124741422003Two percent of men with early-onset prostate cancer harbor germline mutations in the BRCA2 gene.Edwards SM et al
    182640972008Multiple newly identified loci associated with prostate cancer susceptibility.Eeles RA et al
    172877232007A recurrent mutation in PALB2 in Finnish cancer families.Erkko H et al
    100530121999Evidence for a rare prostate cancer-susceptibility locus at chromosome 1p36.Gibbs M et al
    121468522002Segregation analysis of prostate cancer in 1,719 white, African-American and Asian-American families in the United States and Canada.Gong G et al
    93544261997Early age at diagnosis in families providing evidence of linkage to the hereditary prostate cancer locus (HPC1) on chromosome 1.Grönberg H et al
    182640982008Common sequence variants on 2p15 and Xp11.22 confer susceptibility to prostate cancer.Gudmundsson J et al
    78292451995Prostate cancer risk in U.S. blacks and whites with a family history of cancer.Hayes RB et al
    159481492005Familial association of prostate cancer with other cancers in the Swedish Family-Cancer Database.Hemminki K et al
    108915142000Environmental and heritable factors in the causation of cancer--analyses of cohorts of twins from Sweden, Denmark, and Finland.Lichtenstein P et al
    105013581999Association of mis-sense substitution in SRD5A2 gene with prostate cancer in African-American and Hispanic men in Los Angeles, USA.Makridakis NM et al
    127839362003New paraoxonase 1 polymorphism I102V and the risk of prostate cancer in Finnish men.Marchesani M et al
    114053272001Relatives of prostate cancer patients have an increased risk of prostate and stomach cancers: a population-based, cancer registry study in Finland.Matikaine MP et al
    75851881995Evidence of an X-linked or recessive genetic component to prostate cancer risk.Monroe KR et al
    129158802003Role of genetic polymorphisms of the RNASEL gene on familial prostate cancer risk in a Japanese population.Nakazato H et al
    75850191995The impact of family history on early detection of prostate cancer.Narod SA et al
    165377042006RNASEL mutation screening and association study in Ashkenazi and non-Ashkenazi prostate cancer patients.Orr-Urtreger A et al
    172033022007Segregation analysis of 1,546 prostate cancer families in Finland shows recessive inheritance.Pakkanen S et al
    184693422008No association between the SRD5A2 gene A49T missense variant and prostate cancer risk: lessons learned.Pearce CL et al
    119415392002Germline alterations of the RNASEL gene, a candidate HPC1 gene at 1q25, in patients and families with prostate cancer.Rökman A et al
    95855901998Evidence for autosomal dominant inheritance of prostate cancer.Schaid DJ et al
    147493512004The complex genetic epidemiology of prostate cancer.Schaid DJ et al
    111562392000A genetic epidemiological study of hereditary prostate cancer (HPC) in Finland: frequent HPCX linkage in families with late-onset disease.Schleutker J et al
    146129112003CHEK2 variants associate with hereditary prostate cancer.Seppälä EH et al
    89102761996Major susceptibility locus for prostate cancer on chromosome 1 suggested by a genome-wide search.Smith JR et al
    111757852001A candidate prostate cancer susceptibility gene at chromosome 17p.Tavtigian SV et al
    182640962008Multiple loci identified in a genome-wide association study of prostate cancer.Thomas G et al
    126756882003Segregation analysis of prostate cancer in France: evidence for autosomal dominant inheritance and residual brother-brother dependence.Valeri A et al
    111641512001Autosomal dominant inheritance of prostate cancer: a confirmatory study.Verhage BA et al
    97717111998Evidence for a prostate cancer susceptibility locus on the X chromosome.Xu J et al
    122443202002Germline mutations and sequence variants of the macrophage scavenger receptor 1 gene are associated with prostate cancer risk.Xu J et al
    174013632007Genome-wide association study of prostate cancer identifies a second risk locus at 8q24.Yeager M et al

    External Links